Track topics on Twitter Track topics that are important to you
Bristol-Myers Squibb Company - Equities research analysts at Leerink Swann lifted their Q3 2017 EPS estimates for Bristol-Myers Squibb in a research note issued to investors on Friday. Leerink Swann analyst S. Fernandez now forecasts that the biopharmaceutical company will post earnings of $0.72 per share for the quarter, up from their prior estimate of $0.71.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...